Health TidingsImvax Advances IGV-001 Toward Phase 3 After FDA Alignment in High-Risk Glio... Imvax Advances IGV-001 Toward Phase 3 After FDA Alignment in High-Risk Glio... Read Post »
Health TidingsArrowhead ARO-DIMER-PA Cuts PCSK9 72% and APOC3 88% Arrowhead ARO-DIMER-PA Cuts PCSK9 72% and APOC3 88% Read Post »
Health TidingsBioVie’s Bezisterim Shows Promise in Long COVID Patients with High Sympto... BioVie’s Bezisterim Shows Promise in Long COVID Patients with High Sympto... Read Post »
Health TidingsBH-30643 Shows 45% Response Rate in EGFR C797S NSCLC BH-30643 Shows 45% Response Rate in EGFR C797S NSCLC Read Post »
Clinical TrialsXKH004 Delivers Phase 3 Efficacy in Ankylosing Spondylitis With 45.4% ASAS4... XKH004 Delivers Phase 3 Efficacy in Ankylosing Spondylitis With 45.4% ASAS4... Read Post »
Clinical TrialsIvonescimab Shows Sustained Overall Survival Benefit in EGFR-Mutated NSCLC ... Ivonescimab Shows Sustained Overall Survival Benefit in EGFR-Mutated NSCLC ... Read Post »
Clinical TrialsTRUTAKNA Stabilized Kidney Function and Reduced Risk of Kidney Disease Prog... TRUTAKNA Stabilized Kidney Function and Reduced Risk of Kidney Disease Prog... Read Post »
New Drug ApprovalFDA Approves Curium’s BEXLUTRY as First Radioligand Equivalent to LUTATHE... FDA Approves Curium’s BEXLUTRY as First Radioligand Equivalent to LUTATHE... Read Post »
Health TidingsPerspective Adds Keytruda to Phase 1/2a Trial of FAP-Targeted Alpha Therapy... Perspective Adds Keytruda to Phase 1/2a Trial of FAP-Targeted Alpha Therapy... Read Post »
New Drug ApprovalFDA Approves Ameluz PDT for Superficial Basal Cell Carcinoma FDA Approves Ameluz PDT for Superficial Basal Cell Carcinoma Read Post »
Health TidingsFDA Grants RASONQUE Breakthrough Therapy Designation for First-Line PDAC FDA Grants RASONQUE Breakthrough Therapy Designation for First-Line PDAC Read Post »
Health TidingsBeta Bionics Mint Patch Pump Wins FDA Clearance Beta Bionics Mint Patch Pump Wins FDA Clearance Read Post »
Clinical TrialsContineum’s JNJ-5120/PIPE-307 Misses Phase 2 MDD Endpoint Contineum’s JNJ-5120/PIPE-307 Misses Phase 2 MDD Endpoint Read Post »
Health TidingsFDA Shortens Initial IMDELLTRA Monitoring for Patients With ES-SCLC FDA Shortens Initial IMDELLTRA Monitoring for Patients With ES-SCLC Read Post »
Clinical TrialsRevelyx Bio’s Recombinant Botulinum Toxin YY003 Shows 80.8% Response in P... Revelyx Bio’s Recombinant Botulinum Toxin YY003 Shows 80.8% Response in P... Read Post »
Clinical TrialsTrastuzumab Botidotin Improves Progression-Free Survival Versus T-DM1 in HE... Trastuzumab Botidotin Improves Progression-Free Survival Versus T-DM1 in HE... Read Post »
Health TidingsDefinium’s DT120 ODT Delivers Positive Phase 3 Results in GAD Definium’s DT120 ODT Delivers Positive Phase 3 Results in GAD Read Post »
Clinical TrialsCorbus’s CRB-913 Shows 5% Weight Loss in Phase 1b Obesity Trial Corbus’s CRB-913 Shows 5% Weight Loss in Phase 1b Obesity Trial Read Post »
Health TidingsTakeda Zasocitinib Gets FDA Priority Review for Psoriasis Takeda Zasocitinib Gets FDA Priority Review for Psoriasis Read Post »
Clinical TrialsEnhertu Extends Progression-Free Survival by Six Months in First-Line HER2-... Enhertu Extends Progression-Free Survival by Six Months in First-Line HER2-... Read Post »
Clinical TrialsZipalertinib Plus Chemotherapy Improves Progression-Free Survival in First-... Zipalertinib Plus Chemotherapy Improves Progression-Free Survival in First-... Read Post »
Health TidingsAstraZeneca’s Tagrisso Improves Long-Term Survival in Early-Stage EGFR-Mu... AstraZeneca’s Tagrisso Improves Long-Term Survival in Early-Stage EGFR-Mu... Read Post »
Health TidingsGotistobart Extends Median Survival to 18.5 Months in Previously Treated Sq... Gotistobart Extends Median Survival to 18.5 Months in Previously Treated Sq... Read Post »
New Drug ApprovalFDA Approves Pixclara as First FET-PET Imaging Drug for Glioma FDA Approves Pixclara as First FET-PET Imaging Drug for Glioma Read Post »
Health TidingsJ&J’s Amivantamab Plus Chemotherapy Delivers 34.3-Month Median Overal... J&J’s Amivantamab Plus Chemotherapy Delivers 34.3-Month Median Overal... Read Post »
Clinical TrialsZidesamtinib Shows 94% Response Rate in ROS1-Positive NSCLC Zidesamtinib Shows 94% Response Rate in ROS1-Positive NSCLC Read Post »
Clinical TrialsRis-Rez Extends Survival in Relapsed Small Cell Lung Cancer in Phase III AR... Ris-Rez Extends Survival in Relapsed Small Cell Lung Cancer in Phase III AR... Read Post »
Clinical TrialsRoche’s Tam-Peli Cuts Death Risk by 54% in SCLC Trial Roche’s Tam-Peli Cuts Death Risk by 54% in SCLC Trial Read Post »
New Drug ApprovalPharming Wins FDA Approval to Expand Joenja to Children With APDS Pharming Wins FDA Approval to Expand Joenja to Children With APDS Read Post »
Health TidingsFDA Extends Review of Zanzalintinib Combination in Metastatic Colorectal Ca... FDA Extends Review of Zanzalintinib Combination in Metastatic Colorectal Ca... Read Post »
New Drug ApprovalFDA Approves ISEMBYLD as First Muscle-Targeted Therapy for Spinal Muscular ... FDA Approves ISEMBYLD as First Muscle-Targeted Therapy for Spinal Muscular ... Read Post »
Health TidingsFDA Grants Orphan Drug Designation to Asedebart for Cushing’s Syndrome FDA Grants Orphan Drug Designation to Asedebart for Cushing’s Syndrome Read Post »
Health TidingsBIO101 potential GLP-1 complement advances toward Phase 2 obesity trial BIO101 potential GLP-1 complement advances toward Phase 2 obesity trial Read Post »
Health TidingsKyowa Kirin’s KHK4951 Eye Drop Misses Phase 2 Endpoint in Neovascular AMD Kyowa Kirin’s KHK4951 Eye Drop Misses Phase 2 Endpoint in Neovascular AMD Read Post »
Clinical TrialsStructure Advances Oral Obesity Pipeline With ACCG-2671 and Aleniglipron Da... Structure Advances Oral Obesity Pipeline With ACCG-2671 and Aleniglipron Da... Read Post »
Health TidingsGSK Wins Japan Approval for Ready-to-Use Shingrix Prefilled Syringe GSK Wins Japan Approval for Ready-to-Use Shingrix Prefilled Syringe Read Post »
Health TidingsImmutep Refocuses Efti Development on HNSCC and STS Immutep Refocuses Efti Development on HNSCC and STS Read Post »
Clinical TrialsRedasemtide Shows DEB Ulcer Closure, Misses Stroke Endpoint Redasemtide Shows DEB Ulcer Closure, Misses Stroke Endpoint Read Post »
Clinical TrialsFinal MATTERHORN Analysis Confirms Overall Survival Benefit With Durvalumab... Final MATTERHORN Analysis Confirms Overall Survival Benefit With Durvalumab... Read Post »
Health TidingsFirst Generative AI-Discovered Drug Advances to Phase III Human Studies First Generative AI-Discovered Drug Advances to Phase III Human Studies Read Post »
Clinical TrialsSetmelanotide Shows BMI and Metabolic Benefits in Paediatric Hypothalamic O... Setmelanotide Shows BMI and Metabolic Benefits in Paediatric Hypothalamic O... Read Post »
Clinical TrialsAtogepant Cuts Menstrual Migraine Days in Phase 3 LUNA Study Atogepant Cuts Menstrual Migraine Days in Phase 3 LUNA Study Read Post »
Clinical TrialsTNP-2092 Shows 100% Six-Month Success in Phase IIa Non-Surgical PJI Trial TNP-2092 Shows 100% Six-Month Success in Phase IIa Non-Surgical PJI Trial Read Post »
Clinical TrialsFDA Pauses New Enrollment in Biohaven’s Opakalim Epilepsy Program Over Ro... FDA Pauses New Enrollment in Biohaven’s Opakalim Epilepsy Program Over Ro... Read Post »
Clinical TrialsOpus Genetics Reports Visual Function Gains with OPGx-BEST1 in Phase 1/2 BE... Opus Genetics Reports Visual Function Gains with OPGx-BEST1 in Phase 1/2 BE... Read Post »
Clinical TrialsTT-P34 Phase 1 Trial Shows CNS Exposure in Parkinson’s TT-P34 Phase 1 Trial Shows CNS Exposure in Parkinson’s Read Post »
Health TidingsRoche’s Enspryng Wins FDA Priority Review for MOGAD After 68% Relapse-Ris... Roche’s Enspryng Wins FDA Priority Review for MOGAD After 68% Relapse-Ris... Read Post »
Clinical TrialsVOXZOGO (Vosoritide) Shows Significant Growth Improvements in Phase 3 Hypoc... VOXZOGO (Vosoritide) Shows Significant Growth Improvements in Phase 3 Hypoc... Read Post »
Clinical TrialsNeflamapimod Biomarker Data Set to Shed Light on Tau-Driven FTD in Phase 2a... Neflamapimod Biomarker Data Set to Shed Light on Tau-Driven FTD in Phase 2a... Read Post »
Clinical TrialsDISC-3405 Reduces Phlebotomy and Controls Hematocrit in Phase 2 Polycythemi... DISC-3405 Reduces Phlebotomy and Controls Hematocrit in Phase 2 Polycythemi... Read Post »
